Emily S. Winn-Deen
Dr. Winn-Deen received her B.S. in Chemistry from Lehigh University and her Ph.D. in Chemistry from Boston University, and has over 20 years of experience in diagnostics product development. Currently she is vice president for strategic planning and business development at Cepheid, a small genetic analysis company focusing on rapid nucleic acid testing located in Sunnyvale, CA. Her career has included development of clinical chemistry reagents, urinalysis strips, immunoassays, FISH probes, and DNA diagnostics. As an R&D group leader at Applied Biosystems, Dr. Winn-Deen managed the team developing their cystic fibrosis assay, and as director of diagnostics R&D at Oncor, Inc. she led the team developing novel DNA-based cancer assays including the first FDA approved test for HER2/neu. While at Celera Genomics she directed the high throughput genotyping laboratory and was responsible for developing genotyping assays to facilitate establishing the correlation between human polymorphisms and various medically important traits. Most recently she was senior director of the genomics business area at Roche Molecular Systems in Pleasanton, CA, where she was involved in translating genetic research findings for complex disease into DNA diagnostic products. She has served as Principal Investigator or Co-Investigator on funded grants from the NIST Advanced Technology Program, the National Cancer Institute, and the US Department of Defense, and on grant review committees for the National Institute of Allergy and Infectious Disease and the National Cancer Institute. In 2000 she was elected to be a Fellow in the National Academy of Clinical Biochemistry, and in 2003 she was one of 13 scientists appointed to the HHS Secretary’s Advisory Committee on Genetics, Health and Society (SACGHS). Dr. Winn-Deen is the author of numerous abstracts, research articles, and book chapters, is the holder of over a dozen patents, and serves as a regular reviewer for a variety of scientific journals.